New drug combo tested for Tough-to-Treat cancers

NCT ID NCT04282018

Summary

This early-phase study tested the safety and best dose of a new drug called BGB-10188. It was given alone or combined with other cancer drugs to 97 patients with advanced blood cancers or solid tumors that had returned or stopped responding to prior treatments. The main goal was to see how much of the drug patients could tolerate and to gather initial safety information.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Affiliated Zhongshan Hospital of Fudan University

    Shanghai, Shanghai Municipality, 200032, China

  • Austin Health

    Heidelberg, Victoria, 3084, Australia

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, 100142, China

  • Blacktown Cancer and Haematology Centre

    Blacktown, New South Wales, 2148, Australia

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, 200000, China

  • Fujian Cancer Hospital

    Fuzhou, Fujian, 350014, China

  • Gallipoli Medical Research Foundation

    Greenslopes, Queensland, 4120, Australia

  • General Hospital of Ningxia Medical University

    Yinchuan, Ningxia, 750004, China

  • Henan Cancer Hospital

    Zhengzhou, Henan, 450000, China

  • Hubei Cancer Hospital

    Wuhan, Hubei, 430079, China

  • Jining No Peoples Hospital West Branch

    Jining, Shandong, 272000, China

  • Monash Health

    Clayton, Victoria, 3168, Australia

  • Peking University Shenzhen Hospital

    Shenzhen, Guangdong, 518036, China

  • Perth Blood Institute

    West Perth, Western Australia, 6005, Australia

  • Pindara Private Hospital

    Benowa, Queensland, 4217, Australia

  • Royal Adelaide Hospital

    Adelaide, South Australia, 5000, Australia

  • Saint Vincents Hospital Sydney

    Darlinghurst, New South Wales, 2010, Australia

  • The First Affiliated Hospital of Soochow University

    Suzhou, Jiangsu, 215006, China

  • The First Affiliated Hospital of Wenzhou Medical University

    Wenzhou, Zhejiang, 325000, China

  • The First Hospital of Jilin University

    Changchun, Jilin, 130021, China

  • The Third Xiangya Hospital of Central South University

    Changsha, Hunan, 410013, China

  • Union Hospital of Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, 430022, China

  • West China Hospital, Sichuan University

    Chengdu, Sichuan, 610041, China

  • Zhejiang University College of Medicine Second Affiliated Hospital

    Hangzhou, Zhejiang, 310009, China

Conditions

Explore the condition pages connected to this study.